MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):317-323. doi: 10.15585/mmwr.mm6912a1.
Methamphetamine is a highly addictive central nervous system stimulant. Methamphetamine use is associated with a range of health harms, including psychosis and other mental disorders, cardiovascular and renal dysfunction, infectious disease transmission, and overdose (1,2). Although overall population rates of methamphetamine use have remained relatively stable in recent years (3), methamphetamine availability and methamphetamine-related harms (e.g., methamphetamine involvement in overdose deaths and number of treatment admissions) have increased in the United States* (4,5); however, analyses examining methamphetamine use patterns and characteristics associated with its use are limited. This report uses data from the 2015-2018 National Surveys on Drug Use and Health (NSDUHs) to estimate methamphetamine use rates in the United States and to identify characteristics associated with past-year methamphetamine use. Rates (per 1,000 adults aged ≥18 years) for past-year methamphetamine use were estimated overall, by demographic group, and by state. Frequency of past-year use and prevalence of other substance use and mental illness among adults reporting past-year use were assessed. Multivariable logistic regression examined characteristics associated with past-year use. During 2015-2018, the estimated rate of past-year methamphetamine use among adults was 6.6 per 1,000. Among adults reporting past-year methamphetamine use, an estimated 27.3% reported using on ≥200 days, 52.9% had a methamphetamine use disorder, and 22.3% injected methamphetamine. Controlling for other factors, higher adjusted odds ratios for past-year use were found among men; persons aged 26-34, 35-49, and ≥50 years; and those with lower educational attainment, annual household income <$50,000, Medicaid only or no insurance, those living in small metro and nonmetro counties, and those with co-occurring substance use and co-occurring mental illness. Additional efforts to build state and local prevention and response capacity, expand linkages to care, and enhance public health and public safety collaborations are needed to combat increasing methamphetamine harms.
甲基苯丙胺是一种高度成瘾的中枢神经系统兴奋剂。甲基苯丙胺的使用与一系列健康危害有关,包括精神病和其他精神障碍、心血管和肾功能障碍、传染病传播以及过量用药(1,2)。尽管近年来总体人口中甲基苯丙胺的使用率相对稳定(3),但在美国,甲基苯丙胺的供应和与甲基苯丙胺相关的危害(例如,甲基苯丙胺在过量死亡和治疗入院人数中的参与)有所增加(4,5);然而,分析甲基苯丙胺使用模式和与其使用相关的特征的分析有限。本报告使用 2015-2018 年全国毒品使用和健康调查(NSDUHs)的数据,估计美国的甲基苯丙胺使用率,并确定与过去一年使用甲基苯丙胺相关的特征。总体上、按人口统计学群体和按州估计过去一年甲基苯丙胺使用率。评估报告过去一年使用甲基苯丙胺的成年人中过去一年的使用频率和其他物质使用和精神疾病的流行率。多变量逻辑回归检查了与过去一年使用相关的特征。在 2015-2018 年期间,估计成年人过去一年使用甲基苯丙胺的比率为每 1000 人 6.6 人。在报告过去一年使用甲基苯丙胺的成年人中,估计有 27.3%的人使用甲基苯丙胺的天数≥200 天,52.9%的人有甲基苯丙胺使用障碍,22.3%的人注射甲基苯丙胺。在控制其他因素的情况下,过去一年使用的调整后比值比在男性中更高;年龄在 26-34 岁、35-49 岁和≥50 岁的人;以及教育程度较低、年收入<50,000 美元、仅拥有医疗补助或没有保险、居住在小都会区和非都会区以及同时存在物质使用和同时存在精神疾病的人。需要进一步努力建立州和地方预防和应对能力,扩大与护理的联系,并加强公共卫生和公共安全合作,以应对不断增加的甲基苯丙胺危害。
MMWR Morb Mortal Wkly Rep. 2020-3-27
JAMA Psychiatry. 2021-12-1
Subst Use Misuse. 2017-7-3
Drug Alcohol Depend. 2017-11-16
Subst Abuse Treat Prev Policy. 2008-7-25
Online J Public Health Inform. 2025-8-12
Front Public Health. 2025-4-2
Health Aff (Millwood). 2017-10-1
Drug Alcohol Rev. 2017-3
J Psychiatry Neurosci. 2006-9
Nicotine Tob Res. 2004-4